Chronic Periodontitis Market

Key Highlights 

• The chronic periodontitis market is expected to grow significantly by 2036.
• Approved products for chronic periodontitis include ARESTIN (minocycline hydrochloride microspheres) and REGROTH Dental Kit (trafermin), while the pipeline remains sparse in the 7 MM, with GPV381 in development outside major markets, highlighting the need for disease-modifying innovation.

DelveInsight's "Chronic Periodontitis Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of the Chronic Periodontitis, historical and forecasted epidemiology as well as the Chronic Periodontitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Periodontitis market report provides current treatment practices, emerging drugs, Chronic Periodontitis market share of the individual therapies, current and forecasted Chronic Periodontitis market Size from 2022 to 2036 segmented by seven major markets. The Report also covers current Chronic Periodontitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Chronic Periodontitis market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2022-2036

Key Factors Driving the Growth of the Chronic Periodontitis Market

• Rising Global Prevalence of Periodontal Disease: Chronic periodontitis represents a substantial global oral-health burden, with severe periodontal disease affecting more than 1 billion people worldwide. The increasing disease burden is expected to support demand for periodontal diagnostics, therapeutics, and professional dental care.
• Growing Geriatric Population: The prevalence of severe periodontal disease increases with age, peaking around the mid-50s and remaining elevated among older adults. Population aging is therefore expected to expand the pool of patients requiring long-term periodontal management and tooth-preservation treatments.
• Increasing Prevalence of Diabetes: Diabetes is closely associated with the development and progression of periodontal disease, while periodontitis can also complicate glycemic management. Growing awareness of this two-way relationship is encouraging greater integration of dental examinations and periodontal care into diabetes management.
• High Tobacco Consumption and Other Lifestyle Risk Factors: Tobacco use is a major behavioral risk factor for periodontal disease, while poor oral hygiene, unhealthy diets, and other lifestyle factors can further increase oral-health risks. Continued exposure to these factors contributes to the underlying patient pool for chronic periodontitis treatment.

Chronic Periodontitis Disease Understanding and Treatment Algorithm

Chronic periodontitis is a long-standing inflammatory disease of the supporting structures of the teeth, characterized by progressive periodontal attachment loss and alveolar bone destruction, leading to deep periodontal pockets, tooth mobility, and eventual tooth loss if left unaddressed.

Symptoms include gingival inflammation and bleeding, periodontal pocket formation, progressive attachment and bone loss, and tooth mobility, largely caused by pathogenic oral bacteria that accumulate with poor oral hygiene, forming plaque that hardens into calculus, and further influenced by host immune dysregulation, genetic susceptibility, smoking, and systemic risk factors.

Chronic Periodontitis Diagnosis

Chronic periodontitis is diagnosed through clinical evaluation of probing depths, attachment loss, and bleeding on probing, supported by intraoral dental X-rays or an orthopantomogram (OPG) to assess alveolar bone loss and deep periodontal pockets.

Chronic Periodontitis Treatment

The treatment landscape for chronic periodontitis includes non-surgical scaling and root planing with adjunctive antimicrobials and surgical options such as periodontal flap procedures and regenerative grafting, supported by patient education on oral hygiene.

Approved products for chronic periodontitis include ARESTIN (minocycline hydrochloride microspheres) and REGROTH Dental Kit (trafermin), while the pipeline remains sparse in the 7 MM, with GPV381 in development outside major markets, highlighting the need for disease-modifying innovation.

Chronic Periodontitis Epidemiology 

The Chronic Periodontitis epidemiology section provides insights about the historical and current Chronic Periodontitis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Chronic Periodontitis market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Periodontitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2022 to 2036.

• Secondary research indicates that approximately 42% of dentate US adults aged 30 years and older are affected by periodontitis, highlighting the substantial public health burden of chronic periodontal disease across the adult population in the US.
• In the US, secondary research indicates that 8.7% of adults have mild periodontitis, 30.0% have moderate disease, and 8.5% are affected by severe periodontitis, reflecting a substantial burden across disease severities.
• Secondary research across Europe indicates that chronic periodontitis prevalence rises sharply from the 30s, peaks in adults aged 65–74 years, and remains rare in younger populations, which account for only around 1.7% of cases.
• In the UK, secondary research indicates that periodontitis affects nearly half of the adult population and approximately 60% of individuals aged over 65 years, underscoring its status as one of the most prevalent chronic inflammatory diseases and a significant public health concern nationwide.
• In the US, secondary research suggests that periodontitis disproportionately affects men (approximately 57%) compared with women (around 39%), underscoring a clear gender-related difference in disease burden and its broader public health significance.
• In Japan, secondary research indicates that periodontitis affects nearly half of the population, with an estimated prevalence of 49.4%, highlighting its widespread nature and significant public health impact nationwide.

Chronic Periodontitis Drug Chapters

The drug chapter segment of the Chronic Periodontitis report encloses the detailed analysis of Chronic Periodontitis marketed drugs and late-stage (Phase-III and Phase-II) Chronic Periodontitis pipeline drugs. It also helps to understand the Chronic Periodontitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Chronic Periodontitis Marketed Drugs

ARESTIN (Minocycline Hydrochloride): Bausch Health

ARESTIN (minocycline hydrochloride microspheres) is a locally delivered, sustained-release antibiotic placed into periodontal pockets after scaling and root planing, providing targeted antimicrobial activity to reduce pathogenic bacteria and support periodontal pocket depth reduction.
In February 2001, the US FDA approved ARESTIN (minocycline hydrochloride microspheres) for use as an adjunct to scaling and root planing in the treatment of adult periodontitis.

REGROTH Dental Kit (trafermin): Kaken

REGROTH Dental Kit (trafermin) is a locally applied recombinant basic fibroblast growth factor formulation used during periodontal surgery to stimulate periodontal tissue regeneration by promoting angiogenesis and proliferation of periodontal ligament and alveolar bone–forming cells at defect sites.
In October 2016, Kaken Pharmaceutical received regulatory approval in Japan for REGROTH Dental Kit (trafermin) for periodontal regeneration in patients with periodontitis involving alveolar bone destruction.

Chronic Periodontitis Emerging Drugs

GPV381: Denteric

GPV381, developed by Denteric, is an investigational immunotherapy for periodontitis that targets key virulence factors of Porphyromonas gingivalis, aiming to modulate host–pathogen interactions and address underlying inflammatory drivers of periodontal tissue destruction. GPV381 is currently in Phase I clinical development. In February 2024, Denteric reported the dosing of the first subjects in its first-in-human safety study of GPV381, an investigational therapy being developed for the treatment of severe periodontal disease.

Chronic Periodontitis Market Outlook

The Chronic Periodontitis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic Periodontitis market trends by analyzing the impact of current Chronic Periodontitis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Chronic Periodontitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chronic Periodontitis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Chronic Periodontitis market in 7MM is expected to witness a major change in the study period 2022-2036.

Chronic Periodontitis Drugs Uptake

This section focuses on the rate of uptake of the potential Chronic Periodontitis drugs recently launched in the Chronic Periodontitis market or expected to get launched in the market during the study period 2022-2036. The analysis covers Chronic Periodontitis market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Chronic Periodontitis Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Chronic Periodontitis market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Periodontitis Pipeline Development Activities

The Chronic Periodontitis report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chronic Periodontitis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Chronic Periodontitis report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Chronic Periodontitis emerging therapies.

Reimbursement Scenario in Chronic Periodontitis

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Chronic Periodontitis market trends, we take KOLs and SMEs ' opinion working in the Chronic Periodontitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Periodontitis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Chronic Periodontitis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Chronic Periodontitis Market Report

• The Chronic Periodontitis Therapeutics Market Report covers a segment of key events, an executive summary, a descriptive overview, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along Chronic Periodontitis Treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current Chronic Periodontitis Treatment landscape.
• A detailed review of the Chronic Periodontitis Therapeutics Market, historical and forecasted Chronic Periodontitis Treatment Market Size, Chronic Periodontitis Drugs Market Share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Chronic Periodontitis Therapeutics Market Report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Chronic Periodontitis Drugs Market.

Chronic Periodontitis Market Report Insights

• Chronic Periodontitis Patient Population Forecast
• Chronic Periodontitis Therapeutics Market Size
• Chronic Periodontitis Pipeline Drugs Analysis
• Chronic Periodontitis Market Size and Trends
• Chronic Periodontitis Therapeutics Market Opportunity (Current and Forecasted)

Chronic Periodontitis Market Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI) - enabled Market Research Report
• 11-year forecast
• Chronic Periodontitis Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Chronic Periodontitis Treatment Addressable Market (TAM)
• Chronic Periodontitis Competitive Landscape
• Chronic Periodontitis Major Companies Insights
• Chronic Periodontitis Price Trends and Analogue Assessment
• Chronic Periodontitis Therapies Drug Adoption/Uptake
• Chronic Periodontitis Therapies Peak Patient Share Analysis

Chronic Periodontitis Market Report Assessment

• Chronic Periodontitis Current Treatment Practices
• Chronic Periodontitis Unmet Needs
• Chronic Periodontitis Clinical Development Analysis
• Chronic Periodontitis Emerging Drugs Product Profiles
• Chronic Periodontitis Market Attractiveness
• Chronic Periodontitis Qualitative Analysis (SWOT and Attribute analysis)

Key Questions Answered in the Chronic Periodontitis Treatment Market Report

Chronic Periodontitis Therapeutics Market Insights

• What was the Chronic Periodontitis Treatment Market Size, the Chronic Periodontitis Market Size by therapies, Chronic Periodontitis Drugs Market Share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Chronic Periodontitis?
• What are the disease risks, burdens, and unmet needs of Chronic Periodontitis? 
• What will be the growth opportunities across the 7MM concerning the patient population with Chronic Periodontitis?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Chronic Periodontitis? What are the current guidelines for treating Chronic Periodontitis in the US, Europe, and Japan?

Reasons to Buy the Chronic Periodontitis Therapeutics Market Report

• The Chronic Periodontitis Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Chronic Periodontitis Drugs Market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease Chronic Periodontitis Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Chronic Periodontitis Drugs Market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the Chronic Periodontitis Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis, ranking of class-wise potential current, and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Chronic Periodontitis Drugs Market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)   enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.